Literature DB >> 28303518

Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation.

Takashi Ishihara1, Keiji Nogami2, Tomoko Matsumoto1, Akitaka Nomura1, Yasufumi Takeshita1, Satoshi Ochi1, Midori Shima1.   

Abstract

The pathogenesis of sinusoidal obstruction syndrome (SOS) and thrombotic microangiopathy (TMA) after hematopoietic stem cell transplantation (HSCT) is poorly understood, and limited information is available on global hemostatic function in HSCT. We assessed changes in coagulation and fibrinolysis using a simultaneous thrombin and plasmin generation assay (T/P-GA) during HSCT. Measurements of endogenous thrombin potential (T-EP) and plasmin peak height (P-Peak) using T/P-GA in six pediatric acute leukemia patients treated with HSCT were compared to normal plasma. In the SOS case, the ratios of T-EP and P-Peak to normal were simultaneously decreased at four weeks post-HSCT (Pre; ~1.1/1.1-1.4, Week+4; 0.14/0.0084, respectively). Similarly, in the TMA patient, both ratios were decreased at 3 weeks and recovered after 8 weeks (Pre; 1.2/~0.95, Week+3; 0.59/0.22, Week+8; 1.2/0.64-0.85). In the other patients, when SOS/TMA was not evident, the T/P-GA data remained within normal limits. These findings suggest that the simultaneous reduction of coagulation and fibrinolytic function in patients developing SOS/TMA can lead to a life-threatening coagulopathy. Further research is warranted to clarify global hemostatic function after HSCT to establish optimal supportive therapy for these critical clinical disorders of hemostasis.

Entities:  

Keywords:  Hematopoietic stem-cell transplantation; Sinusoidal obstruction syndrome; Thrombin and plasmin generation assay; Thrombotic microangiopathy

Mesh:

Substances:

Year:  2017        PMID: 28303518     DOI: 10.1007/s12185-017-2213-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials.

Authors:  B E S Gibson; K Wheatley; I M Hann; R F Stevens; D Webb; R K Hills; S S N De Graaf; C J Harrison
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

2.  Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation?

Authors:  S Nomura; R Ozasa; T Nakanishi; S Fujita; M Miyaji; S Mori; T Yokoi; T Ito; K Ishii
Journal:  Thromb Haemost       Date:  2011-04-07       Impact factor: 5.249

Review 3.  Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Corey Cutler; Shelly Carter; Paul Martin; Roberta Adams; Mary Horowitz; James Ferrara; Robert Soiffer; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2005-08       Impact factor: 5.742

Review 4.  Hepatic veno-occlusive disease after bone marrow transplant.

Authors:  E Carreras; A Grañena; C Rozman
Journal:  Blood Rev       Date:  1993-03       Impact factor: 8.250

5.  Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population.

Authors:  Maria Teresa Sartori; Luca Spiezia; Simone Cesaro; Chiara Messina; Myriam Paris; Marta Pillon; Graziella Saggiorato; Antonio Pagnan; Antonio Girolami; Luigi Zanesco; Giuseppe Cella
Journal:  Thromb Haemost       Date:  2005-04       Impact factor: 5.249

6.  Simultaneous measurement of thrombin and plasmin generation to assess the interplay between coagulation and fibrinolysis.

Authors:  Tomoko Matsumoto; Keiji Nogami; Midori Shima
Journal:  Thromb Haemost       Date:  2013-08-29       Impact factor: 5.249

7.  Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD.

Authors:  A Pinomäki; L Volin; L Joutsi-Korhonen; J O Virtanen; M Lemponen; T Ruutu; R Lassila
Journal:  Bone Marrow Transplant       Date:  2009-08-31       Impact factor: 5.483

8.  Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

Authors:  Beverly J Lange; Franklin O Smith; James Feusner; Dorothy R Barnard; Patricia Dinndorf; Stephen Feig; Nyla A Heerema; Carola Arndt; Robert J Arceci; Nita Seibel; Margie Weiman; Kathryn Dusenbery; Kevin Shannon; Sandra Luna-Fineman; Robert B Gerbing; Todd A Alonzo
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

9.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

10.  Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).

Authors:  M Kaleelrahman; J D Eaton; D Leeming; K Bowyer; D Taberner; J Chang; J H Scarffe; R Chopra
Journal:  Hematology       Date:  2003-04       Impact factor: 2.269

View more
  1 in total

1.  First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin.

Authors:  Masahiro Takeyama; Keiji Nogami; Takahiro Kajimoto; Kenichi Ogiwara; Tomoko Matsumoto; Midori Shima
Journal:  Int J Hematol       Date:  2017-06-08       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.